In support of the latter explanation, recent clinical trials in advanced HCC have shown a trend for higher ORRs overall with combined TKI and anti-PD-1 antibody therapy [13, 25] versus anti-PD-1 antibody monotherapy [26] or dual immune-therapy strategies [27, 28]. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.